Clinical Trial Update: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the Leish-111F + MPL-SE vaccine for treatment of mucocutaneous leishmaniasis, focusing on safety and early efficacy signals…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucocutaneous Leishmaniasis

Drugs mentioned

• Leish-111f + MPL-SE vaccine (Leish-111f with MPL-SE adjuvant)

Snippet

Sponsor: Access to Advanced Health Institute (AAHI) | Conditions: Leishmaniasis, Mucocutaneous | Phase 1 | Status: COMPLETED